Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 2315Neoplasms 1678Prostatic Neoplasms 1178Lung Neoplasms 908Colorectal Neoplasms 873Carcinoma, Non-Small-Cell Lung 848Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 510Brain Neoplasms 509Neoplasm Metastasis 456Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 397Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 355Squamous Cell Carcinoma of Head and Neck 355Rectal Neoplasms 336Recurrence 332Hematologic Neoplasms 323Sarcoma 322Colonic Neoplasms 316Lymphoma 310Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Glioma 277Carcinoma, Renal Cell 277

Interventions

senaparib 1niraparib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Ovarian Cancer × 1 year × Clear all
NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Fudan University

Phase 2 Not yet recruiting
37 enrolled
Gynecologic

Advanced Ovarian Cancer

NCT07059676 2025-07-11

LIBINI-1

Clinica Universidad de Navarra, Universidad de Navarra

Not yet recruiting
120 enrolled
Gynecologic

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡